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C-reactive protein (CRP) is a systemic inflammation marker that predicts future cardiovascular risk. CRP levels are higher in African
Americans and Hispanic Americans than in European Americans, but the genetic determinants of CRP in these admixed United States
minority populations are largely unknown. We performed genome-wide association studies (GWASs) of 8,280 African American (AA)
and 3,548 Hispanic American (HA) postmenopausal women from the Women’s Health Initiative SNP Health Association Resource.
We discovered and validated a CRP-associated variant of triggering receptors expressed by myeloid cells 2 (TREM2) in chromosomal
region 6p21 (p ¼ 1010). The TREM2 variant associated with higher CRP is common in Africa but rare in other ancestral populations.
In AAwomen, the CRP region in 1q23 contained a strong admixture association signal (p¼ 1017), which appears to be related to several
independent CRP-associated alleles; the strongest of these is present only in African ancestral populations and is associated with higher
CRP. Of the other genomic loci previously associated with CRP through GWASs of European populations, most loci (LEPR, IL1RN, IL6R,
GCKR, NLRP3, HNF1A, HNF4A, and APOC1) showed consistent patterns of association with CRP in AA and HA women. In summary,
we have identified a common TREM2 variant associatedwith CRP in United Statesminority populations. The genetic architecture under-
lying the CRP phenotype in AA women is complex and involves genetic variants shared across populations, as well as variants specific
to populations of African descent.Introduction
C-reactive protein (CRP) is a systemic inflammation
marker that predicts future cardiovascular risk.1–3 Plasma
CRP levels increase with age and are higher in women
than in men.4–9 African American (AA) and Hispanic
American (HA) individuals have higher concentrations of
CRP than do European American (EA) individuals.4–9
Chronic low-grade inflammation might contribute to
increased cardiovascular disease risk and other health
disparities among these minority United States popula-
tions.10 CRP levels are also correlated with obesity and
other metabolic and atherosclerotic risk factors.11–13 The
correlation between CRP and adiposity does not appear
to completely explain the higher CRP levels in populations
of African descent.12–15 Therefore, other factors, both
genetic and nongenetic, most likely contribute to CRP
differences between racial and ethnic groups.
Family and twin studies suggest that additive genetic
factors account for 25%–40% of the variance in plasma
CRP levels in Europeans16–18 and 45% in AA individ-
uals.19 Recent large genome-wide association studies
(GWASs) conducted on Europeans and Japanese have iden-
tified approximately 20 CRP-associated loci that together
explain ~5% of the variance.20–23 Many of these genes
involve pathways related to either innate immunity (these
are CRP [MIM 123260], IL6R [MIM 147880], IL6 [MIM
147620], NLRP3 [MIM 606416], IL1RN [MIM 147679],1Public Health Sciences Division, Fred Hutchinson Cancer Research Cente
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(these are APOC1 [MIM 107710], HNF1A [MIM 142410],
LEPR [MIM 601007], GCKR [MIM 600842], HNF4A [MIM
600281], RORA [MIM 600825], PPP1R3B [MIM 610541]).
No large CRP GWAS performed to date has included
participants of African or Hispanic ancestry. Recently,
a GWAS was performed on ~800 AA individuals, but no
new loci were discovered.24 Using genotype and pheno-
type data from the Women’s Health Initiative SNP Health
Association Resource (WHI-SHARe), we therefore under-
took a GWAS and local-ancestry analysis of 8,280 AA
participants and a GWAS of 3,548 HA participants. Our
goals were to identify new and possibly ancestry-specific
genetic variants associated with CRP in AA and HAwomen
and to assess the genetic architecture of CRP association in
these women at inflammatory and metabolism loci previ-
ously identified in CRP GWASs of European and Asian
populations.Subjects and Methods
Our overall approach can be summarized as follows. (1) The GWAS
discovery stage consisted of 8,280 WHI-SHARe AA samples and
3,548 HA samples and also included admixture mapping of the
AA population. Because of issues related to heterogeneous
ethnicity within Latinos,25 the lack of availability of an
adequately-sized Native American reference panel (which impacts
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(WHI) HA sample size (compared to the larger AA sample), we did
not perform admixture mapping in the HA sample. (2) Validation
of the CRP-associated locus, as well as functional validation with
expression quantitative trait locus (eQTL) analysis, was performed
for independent cohorts including Candidate Gene Association
Resource (CARe) AA individuals (n ¼ 6,300) and whites from the
Atherosclerosis Risk in Communities (ARIC) study (n ¼ 5,656).
(3) Assessment of transferability of other previously published
loci associated with CRP was performed with the WHI-SHARe
AA and HA samples.Study Subjects
Recruitment for the WHI began in 1993 and ended in 1998 and
was conducted by 40 clinical centers in 24 states and the District
of Columbia.26 At the time of enrollment, all women were
required to be between 50 and 79 years old, postmenopausal,
and expected to remain in the area for at least 3 years. Enrollment
of racial or ethnic minority groups proportionate to the total
minority population of women between 50 and 79 years of age
was a high priority of the WHI. Ten of the 40 WHI clinical centers
with expertise and access to specific minority groups (American
Indian, black, Asian American or Pacific Islander, and Hispanic)
were selected to serve as minority recruitment sites. At the end
of the recruitment period, 161,808 women had joined the WHI,
and about 17% represented racial or ethnic minority groups.
Clinical information was collected by self-report and physical
examination. Certified staff obtained fasting blood samples at
the baseline clinic visit by venipuncture and deposited these
samples into tubes containing ethylenediaminetetraacetic acid.
There were 12,151 self-identified AA and 5,469 self identified HA
WHI subjects who had consented to genetic research and were
eligible for WHI-SHARe. Because of budget constraints, we
randomly selected a subsample of 12,157 of these women: 8,515
(70.1%) AA and 3,642 (66.6%) HA women. DNA was extracted
by the Specimen Processing Laboratory at the Fred Hutchinson
Cancer Research Center from specimens that were collected at
the time of enrollment. All participants provided written informed
consent as approved by local human subjects committees.CRP Measurement
High-sensitivity CRPwasmeasured in serum from a total of 11,962
WHI-SHAReparticipants onaRocheModular PChemistry analyzer
at the University of Minnesota with the use of a latex-particle
enhanced immunoturbidimetric assay kit (Roche Diagnostics,
Indianapolis, IN) The results were reported in mg/l. Median CRP
was 3.50 and the interquartile range was 1.58–7.40. The assay coef-
ficient of variationwas 2.3%. All CRP valueswere natural-log trans-
formed for normalizing the distributions of the phenotypic data.Genotyping and Quality Control
Genome-wide genotyping was performed at Affymetrix on the
Affymetrix 6.0 array with 2 mg of DNA at a concentration of
100 ng/ml. Approximately 1% (n ¼ 99) of samples could not be
genotyped. We excluded samples that had a call rate below 95%
(n ¼ 16), that were duplicates of subjects other than monozygotic
twins (n ¼ 34), or that had a Y chromosome (n ¼ 1). SNPs on the
Y chromosome and Affymetrix quality-control (QC) probes were
excluded from analysis (n ¼ 3,280). We also flagged SNPs that
had call rates, calculated separately for AA and HA individuals,
< 95% and concordance rates < 98%, leaving 871,309 unflagged
SNPs. After exclusions, there were 12,007 unique subjects (8,421The AmericanAA and 3,586 HA), and there was an average call rate of 99.8%
over the unflagged SNPs. We analyzed 188 pairs of blind duplicate
samples. The overall concordance rate was 99.8% (the ranges were
94.5%–100% over samples, 98.3%–100% over samples with call
rates > 98%, and 98.1%–100% over unflagged SNPs).
Genotype Imputation
Imputation was carried out with MaCH.27 After some more strin-
gent filtering, 829,370 genotyped SNPs were used for imputation.
For the imputation in AA samples, we used 240 HapMap 2 (release
22) phased haplotypes from the CEU (Utah residents with
ancestry from northern andwestern Europe from the CEPH collec-
tion) and YRI (Yoruba in Ibadan, Nigeria) reference panels and
were left with a total of 2,203,609 SNPs. To augment the size of
the reference panel and aid imputation accuracy in the remaining
individuals in the study,27 we estimated parameters on a subset of
200 WHI AA subjects and then imputed all WHI AA subjects. For
2,190,779 SNPs, we obtained imputations with a minor allele
frequency (MAF) > 1% and an estimated R2 > 0.3. On a small
test sample (2% of the markers on three chromosomes), the
average R2 was 0.88 and the allelic discordance rate was 2.3%.
For imputation in HA samples, we used a larger reference panel
of HapMap III CEU þMEX (Mexican ancestry in Los Angeles, Cal-
ifornia)þ YRI samples for a total of 1,387,466 SNPs (MAF> 1%), of
which 1,368,178 SNPs met the quality threshold of R2 > 0.3.
Relatedness
We used a random subset of 100,000 SNPs from autosomal chro-
mosomes and the method-of-moments approach to a three-
parameter identity-by-descent (IBD) model28 to compute IBD
coefficients between all pairs of 12,008 subjects. On the basis of
these coefficients, we identified pairs of parents and offspring
(22 pairs and 2 trios), monozygotic twins (five pairs), and siblings
(192 pairs and 5 trios). A more thorough confirmatory analysis
with a pairwise kinship-coefficient estimator,29 as well as the
aforementioned method-of-moments approach, was performed
separately for AA and HA individuals, and it validated these rela-
tionships and identified half siblings (73 pairs). In CRP association
analyses, we included one individual from each relative pair,
typically the one with the higher call rate.
Admixture Estimation and Principal-Component
Analysis
Separately for the AA and the HA samples, we computed eigenvec-
tors by using Eigenstrat30 at 178,101 markers that were in
common between our samples and the reference panels. We also
determined individual ancestral proportions by using Frappe31 at
656,852 autosomal markers. For both of these calculations, we
included 475 publically available samples from ancestral popula-
tions (YRI, CEU, East Asians, and Native Americans).32,33 On the
basis of the Frappe estimates, we identified 56 subjects who were
self-identified as AA but who appeared to have less than 10%
African ancestry. We also flagged one participant with question-
able estimates of both ancestry and relatedness. Because we
cannot exclude the possibility of either a sample mishandling or
a data-entry error, we flagged these 57 samples for exclusion.
Local-Ancestry Estimation
For each AA individual in the sample, locus-specific ancestry (the
probability of whether an individual has 0, 1, or 2 alleles of African
ancestry at each locus) was estimated with the program SABERþ,Journal of Human Genetics 91, 502–512, September 7, 2012 503
Table 1. Characteristics of WHI-SHARe AA and HA Participants
Study AA Women HA Women
Sample size 8,280 3,548
Age (SD) 61.6 years (7.0) 60.2 years (6.7)
Female 100% 100%
BMI (SD) 31.0 kg/m2 (6.7) 28.9 kg/m2 (5.6)
Current smoker 11.6% 6.8%
Diabetes 13.9% 8.3%
Hypertension 55.1% 29.3%
High cholesterol 15.6% 13.7%
Current hormone use 53.5% 61.2%
Median CRP (SD) 3.68 mg/l (7.85) 3.16 mg/l (7.22)
Admixture Proportions
African (SD) 75.9% (15.3) 6.2% (11.9)
European (SD) 20.7% (15.2) 60.1% (20.2)
East Asian (SD) 2.2% (2.7) 1.8% (5.3)
Native American (SD) 1.2% (1.8) 31.9% (20.1)
The following abbreviations are used: AA, African American; HA, Hispanic
American; SD, standard deviation; and BMI, body mass index.an extension of the model described in Tang et al.34 In brief,
SABERþ uses a graphical-model approach to adaptively capture
local haplotype structure within each ancestral population and
thereby more accurately accounts for background linkage dis-
equilibrium (LD). In simulation studies, this method compares
favorably to existing methods in terms of the accuracy and
computational efficiency; its error rate is less than 1.5%. In the
current analysis, phased haplotype data from the HapMap3 CEU
and YRI individuals were augmented as the reference panels. In
simulation studies, SABERþ achieves accuracy similar to that of
HapMix; based on analysis of simulated and real AA genotypes,
the correlation between local-ancestry estimates produced by the
two methods is very high.35
GWAS Data Analysis
GWASs for ln-transformed CRP (excluding the WHI-SHARe study
participants with raw CRP values > 100 mg/dl) were performed
under an additive geneticmodel with the use of covariate-adjusted
linear regression implemented in either PLINK v.1.0728 or
MACH2QTL v.1.08.27 Analyses were conducted separately for
self-identified AA and HA individuals. For direct or imputed geno-
types, allelic dosage at each SNP was used as the independent
variable, adjusted for primary covariates of age and geographic
region. In sensitivity analyses, we additionally adjusted for body
mass index (BMI), hormone therapy, diabetes, and hypertension.
To adjust for population stratification and global admixture, we
also incorporated the first four principal components (PCs) as
covariates in the regression models. Eigenvectors 5–10 showed
no evidence of association with CRP levels. To maintain an overall
type 1 error rate of 5%, we used a threshold of a ¼ 2.5 3 108 to
declare genome-wide statistical significance. This threshold has
been suggested for African ancestry populations on the basis of
estimates of approximately two million independent common-
variant tests in African genomes.36504 The American Journal of Human Genetics 91, 502–512, SeptembTo further assess the potential existence of multiple, indepen-
dent variants influencing a trait at the same locus (allelic heteroge-
neity), we repeated regression analyses, conditional on the most
strongly associated (index) SNP in that region. To assess in the
WHI-SHARe AA and HA individuals trait-associated loci previously
reported in Europeans or Japanese, we evaluated the AA and HA
results (including consistency of direction of effect) for each index
SNP in the regions reported and assessed statistical significance by
a simple Bonferroni adjustment based on the total number of SNPs
assessed with a two-sided hypothesis test.
Admixture Mapping
Using the local-ancestry estimates, we performed an admixture-
mapping analysis to detect variants that are present at different
frequencies among the European and African ancestral popula-
tions. Adjusting for age and genome-wide ancestry proportions
by using the first four PCs, we regressed ln-CRP on locus-specific
ancestry. We performed the admixture scan with and without
additional adjustment for BMI. The critical value for genome-
wide significance level of admixture mapping is substantially
lower than that for the genotype test because the recent history
of admixture gives rise to extensive correlation in local ancestry.
On the basis of previous theoretical analysis and simulation
results, a nominal p value of 7 3 106 yielded a genome-wide
type I error of 0.05.34
Validation of New CRP Association Signals in
Independent Samples
Replication of novel association findings in WHI AA individuals
was performed with GWAS data from 3,548 HA women from
WHI-SHARe, 6,300 AA men and women from the CARe consor-
tium, and 5,656 whites from the ARIC study. Both genotyped
and imputed SNP data were available in the CARe AA,WHI-SHARe
HA, and ARIC white samples. We used a p value of < 0.05 to
declare statistical significance in the replication samples. We
conducted meta-analyses combining data from our discovery
and replication cohorts by using inverse-variance weighted
fixed-effects models to combine beta coefficients and standard
errors from study-level regression results for each SNP to derive
effect estimates and a combined p value. Meta-analyses were im-
plemented in the software METAL.37
Analysis of eQTLs
We assessed the functional effects of newly identified CRP-associ-
ated SNPs on gene expression by querying a publically accessible
database containing genome-wide analysis of 22,305 genes
expressed in peripheral-blood monocytes of 1,467 European
individuals.38Results
Assessment of Global and Local Ancestry in Relation
to CRP in Admixed Populations
WHI participant characteristics are summarized by self-
reported ethnicity in Table 1. Among AA individuals,
mean estimates of genome-wide ancestry proportions
were 76% African, 21% European, <2% Asian, and <2%
Native American. Among HA participants, the mean
estimates were 60% European, 32% Native American, 6%
African, and <2% East Asian. European ancestry waser 7, 2012
Figure 1. Admixture Mapping Scan of CRP in WHI AA Women
Admixture mapping log10 p values are shown on the y axis, and
SNPs are ordered by chromosomal position on the x axis. The
dotted line represents a genome-wide p value significance level
less than approximately 7 3 106 (under the assumption of
7,000 independent tests). There is one strongly genome-wide
significant peak centered around CRP on chromosome 1,
indicating that local African ancestry in this region is associated
with CRP.
Figure 2. Manhattan Plot of CRP in WHI AA Women
Gene regions containing genome-wide significant SNPs (p< 2.53
108) are highlighted in green.negatively correlated with age-adjusted CRP in both AA
(p < 10 3 105) and HA (p ¼ 0.001) individuals; the corre-
lation with European ancestry was attenuated upon adjust-
ment for BMI (p ¼ 0.3 in AA samples and p ¼ 0.05 in HA
samples). In HA individuals, Native American ancestry was
associated with higher age-adjusted CRP (p ¼ 0.0001) and
East Asian ancestry was associated with lower age-adjusted
CRP (p ¼ 0.007); these associations were largely robust to
BMI adjustment (p ¼ 0.001 for Native American ancestry
and p ¼ 0.005 for East Asian ancestry).
In the genome-wide admixture scan,weobserved forCRP
a strong admixture signal spanning a 15Mb region of chro-
mosome 1q (151.5–166.7 Mb; GRCh37/hg19) and found
the peak association (p ¼ 1.45 3 1017) at CRP (159.7 Mb)
(Figure 1). In this region, local African ancestry is associated
with higher CRP. A second, albeit much weaker, ancestry-
association peak is present on chromosome 13q at
108.2 Mb (rs9514697–rs9514698), which is located within
an intron of a large gene designated FAM155A (family with
sequence similarity 155, member A). The function of
FAM155A is unknown, and there are no other biologically
plausible candidate genes in the region. The p value was
borderline significant (6.6 3 106) and was only present
in the BMI-adjusted analysis.
GWAS of CRP in AA and HA Individuals
The results of the GWAS for CRP in AA and HA individuals
under an additive genetic model are shown in Figures 2
and 3. Quantile-quantile plots are shown in Figure S1,
available online. The lead or index SNPs associated with
the CRP phenotype in each genomic region are summa-
rized in Tables 2 and 3, and LD association plots for each
region are shown in Figures S2 and S3. In AA participants,The Americanthe strongest GWAS signal includes CRP, corresponding to
the 1q23 peak observed in the CRP admixture scan. Four
other regions reached genome-wide significance in the
GWAS: 2q13 (IL1F10-IL1RN), 6p21 (TREM2 [MIM
605086]), 12q24 (HNF1A), and 19q13 (TOMM40-APOE
[MIM 608061]). In HA individuals, three regions reached
genome-wide significance: 1p31 (LEPR), 1q23 (CRP), and
12q24 (HNF1A). Repeating the GWAS with additional co-
variate adjustments for BMI, hormone therapy, diabetes,
and hypertension did not appreciably alter the results.
Assessment of Allelic Heterogeneity at the CRP Locus
The magnitude and breadth of the CRP association signal
spanning chromosomal region 1q23 in both the admix-
ture scan and GWAS suggest the possibility of allelic
heterogeneity at this locus.We therefore performed a series
of conditional analyses in which we initially adjusted for
the index SNP rs16827466 and then successively adjusted
the CRP association signal for the most strongly associated
SNP remaining at each step. As shown in Table 4, there was
evidence of at least three independent CRP-associated
alleles. The African-ancestry-specific rs16827466 T allele
is associated with higher CRP and appears to account for
~50% of the local-ancestry association signal in this
region. rs7553007 and rs2808634 are associated with lower
CRP, and the CRP-lowering alleles at each SNP are more
common in European populations than in African popula-
tions. After a simultaneous adjustment for rs16827466,
rs7553007, and rs2808634, the p value for association
between local ancestry and CRP is 0.047. Therefore, these
three CRP variants appear to account for much, but
perhaps not all, of local-ancestry association signal in chro-
mosomal region 1q23.Journal of Human Genetics 91, 502–512, September 7, 2012 505
Figure 3. Manhattan Plot of CRP in WHI HA Women
Gene regions containing genome-wide significant SNPs (p< 2.53
108) are highlighted in green.Interestingly, local African ancestry in chromosomal
region 1q23 is also strongly associated with lower white
blood cell count (WBC) (another inflammation-sensitive
phenotype) in African Americans as a result of a common
African-ancestry-specific null DARC (MIM 613665)
variant, FY*O (rs2814778). In a recent GWAS from Sardi-
nia,20 DARC rs3845624 was reported to be independently
associated with CRP. In the initial WHI AA GWAS,
rs3845624 (MAF ¼ 0.15; imputation R2 ¼ 0.94) was nomi-
nally associated with CRP (p ¼ 2 3 107). However, in the
conditional GWAS (with an adjustment for the three
independently associated CRP variants rs16827466,
rs7553007, and rs2808634), the p value for this SNP was
0.30. Because of the correlation between CRP and WBC
(which accounts for ~5% of CRP phenotypic variation),
we repeated the CRP association analysis in AA individuals
by adjusting for WBC. The FY*O allele at DARC showed
statistically significant association (when we adjusted for
both the three CRP SNPs and WBC; p ¼ 2.4 3 1030).
However, upon adjustment for local ancestry at CRP, the
association disappeared. We emphasize that these results
do not exclude the DARC locus as a functional locus but
rather are constrained by the population genetic structure.
The apparent association between the FY*O allele and CRP
level might represent functional involvement of DARC, or
FY*O might simply tag additional undiscovered CRP-
associated variants in chromosomal region 1q23. In AA
individuals, admixture generates strong LD between
DARC and CRP; therefore, it is difficult to statistically
disentangle the contribution of the two loci.
To assess allelic heterogeneity at additional CRP-associ-
ated loci, we repeated the GWAS in AA individuals by
conditioning on all eight independent, genome-wide
significant CRP-associated SNPs (three from CRP, one
from LEPR, one from IL1RN, one from TREM2, one from506 The American Journal of Human Genetics 91, 502–512, SeptembHNF1A, and one from APOE). There were no additional
association signals.
Discovery and Validation of the CRP-Associated Locus
in Chromosomal Region 6p21
Of the six genomic regions significantly associated with
CRP in either AA or HA individuals or both, only chromo-
somal region 6p21 has not been previously associated with
CRP in any population. The CRP signal in this region is
located within a cluster of genes that encode the triggering
receptors expressed by myeloid cells (TREM) family of
leukocyte receptors, which are involved in the regulation
of proinflammatory cytokines and chemokine production
by neutrophils, monocytes, macrophages, and dendritic
cells. The index SNP rs7748513 is located within the
second intron of TREM2. The rs7748513 variant G allele
associated with higher CRP is common in AA individuals
(MAF ¼ 0.43) but is much less common in other popula-
tions (MAF< 0.05 in HapMap European and Asian popula-
tions). Additional adjustment for local African ancestry
did not alter the association between TREM2 rs7748513
and CRP (beta ¼ 0.102 5 0.020; p ¼ 3.8 3 107).
When stratified by local ancestry and adjusted for global
ancestry, the association between rs7748513 and CRP
was present in the 7,722 AA individuals who carried two
(beta ¼ 0.100 5 0.0232; p < 0.0001) or one (beta ¼
0.122 5 0.041; p < 0.0001) African chromosomes at the
TREM2 locus, but not in the 557 AA individuals who
carried two European chromosomes (beta ¼ 0.222 5
0.190; p ¼ 0.25). However, not surprisingly, the MAF of
rs7748513 is considerably lower (0.04) among those
women carrying two European chromosomes at this locus;
therefore, there is limited power for detecting an associa-
tion in this stratum.
No other SNPs in the TREM cluster reached genome-
wide significance in AA individuals. However, another
African-ancestry-specific coding variant of TREM2,
rs2234253 (MAF ¼ 0.11), was associated with 0.12 5
0.023 higher ln-CRP (p ¼ 3 3 105). Within TREM2 exon
2, rs2234253 encodes a p.Thr96Lys substitution that is pre-
dicted to be deleterious.39 The r2 between rs2234253 and
rs7748513 in WHI-SHARe AA participants was 0.41.
Upon adjustment for rs7748513, the CRP association
with rs2234253 was greatly attenuated but still nominally
significant (beta ¼ 0.063 5 0.030; p ¼ 0.04). Haplotype
analysis showed that the minor allele of rs2234253 (the
p.Lys96 variant) is only present in combination with the
African G variant of rs7748513; thus, these two SNPs
define three common TREM2 haplotypes that are associ-
ated with lower (A/Thr), intermediate (G/Thr), and higher
(G/Lys) CRP (Table 5).
To validate the newly discovered TREM2CRP association
in an independent sample of AA individuals, we performed
association analysis for rs7748513 and rs2234253 in 6,272
AA men and women from the CARe GWAS consortium.
rs7748513 met the significance threshold for association
(0.044 5 0.021 increased ln-CRP; p ¼ 0.037), whereaser 7, 2012
Table 2. Genome-wide Significant SNPs for CRP in AA Women
Chromosomal
Region
Number of
SNPS with
p < 2.5 3 108
Top SNP
in Region
Position
Hg18 Candidate Gene
Minor/
Major
Allele
Minor Allele
Frequency
Effect Size
(Standard
Error) p Value
1q23 131 rs16827466 159,649,
700
CRP, APCS, DARC,
FCER1A, DUSP23,
OR10J1, OR10J5,
OR10J3, OLFML2B,
IFI16, FCRL6
T/C 0.178 0.4199 (0.023) 4.149 3 1073
2q13 1 rs6734238 113,557,501 IL1F10, IL1RN G/A 0.446 0.108 (0.018) 9.3 3 1010
6p21 1 rs7748513 41,235,950 TREM2 G/A 0.432 0.106 (0.018) 8.39 3 109
12q24 5 rs7979473 119,904,643 HNF1A A/G 0.443 0.119 (0.019) 1.45 3 1010
19q13 1 rs1160985 50,095,252 TOMM40 C/T 0.366 0.1343 4.19 3 1013
For each locus, the lead SNP with the smallest p values among the genotyped or imputed SNPs is indicated. Effect size represents the effect of a minor allele on
natural-log-transformed CRP. Positions of the SNPs were derived from dbSNP build 136. Novel CRP associations are shown in bold.rs2234253 did not (0.053 5 0.031 increased ln-CRP;
p ¼ 0.09). When stratified by sex, the rs7748513 associa-
tion was present among the 3,787 AA women (beta ¼
0.070; p ¼ 0.011), but not among the 2,488 AA men
(beta ¼ 0.0013; p ¼ 0.97). The p value for interaction
between TREM2 rs7748513 genotype and sex in CARe AA
individuals was 0.06. Because the association between
the TREM2 genotype and CRP appears to be confined to
women, we meta-analyzed the WHI-SHARe AA discovery
results with the CARe AA validation results in women
only. The combined discovery and validation p values
were 1 3 1010 for rs7748513 and 3 3 106 for rs2234253.
We further assessed the association between TREM2 and
CRP in the 3,548 WHI-SHARe HA women, in whom the
frequency of the rs7748513 G allele was 0.08. In HA
women, the rs7748513 G allele was associated with 0.095
natural-log units higher CRP (p ¼ 0.035), whereas the
rs2234253 coding variant showed a nonsignificant trend
in the same direction (beta ¼ 0.168; p ¼ 0.12). In 5,656
white ARIC study participants, there was no evidence of
association between CRP and rs7748513 (MAF ¼ 0.04;
p ¼ 0.96). When stratified by sex, the results for
rs7748513 were somewhat stronger, though not statisti-
cally significant, in white women (0.0614 higher ln-CRP
in 3,046 white women [p ¼ 0.18]) compared to men
(0.00177 higher ln-CRP in 2,694 white men [p ¼ 0.97]).
Given that TREM-2 has been associated with autoim-
mune and inflammatory diseases40 and that autoimmune
diseases (MIM 109100) are more prevalent in women, weTable 3. Genome-wide Significant SNPs for CRP in HA Women
Chromosomal
Region
Number of SNPs
with p < 5 3 108
Top SNP
in Region
Position
Hg18
Candidate
Gene
1p31 5 rs1805096 65,874,845 LEPR
1q23 3 rs7553007 157,965,173 CRP
12q24 16 rs2259816 119,919,970 HNF1A, OA
C12orf43
For each locus, the lead SNP with the smallest p values among the genotyped or
natural-log-transformed CRP. Positions of the SNPs were derived from dbSNP bu
The Americanstratified the WHI-SHARe AA results by autoimmune-
disease status. In the 2,505 women reporting a history of
autoimmune disease, the rs7748513 G allele was associated
with 0.132 natural-log units higher CRP (p ¼ 3.8 3 104).
In the 5,732 women without autoimmune disease, the
rs7748513 G allele was associated with 0.083 natural-log
units higher CRP (p ¼ 2.2 3 105). The p value for interac-
tion was 0.31.
To assess the effect of the TREM2 rs7748513 G allele on
gene expression, we queried a human monocyte eQTL
database derived from 1,467 European subjects.38 Mono-
cytes are one of the white blood cell subtypes that express
the TREM receptors on their surface. We did not find
evidence for a cis-eQTL in TREM2. Nonetheless, a cis-
eQTL was observed in this region of chromosome 6 for
association with monocyte mRNA levels of TREML4
(MIM 614664) (p ¼ 8.43 3 106), which is located 68 kb
downstream of rs7748513 and is between TREM2 and
TREM1. No additional significant cis- or trans-effects
were observed for TREM2 rs7748513 with the use of
a p threshold of <105.
Assessment of Other Previously Discovered
WBC-Associated Loci in AA Individuals
Eighteen CRP loci have been identified previously in Euro-
pean or Japanese GWASs.20–23 Table S1 shows the associa-
tion results of the originally reported index SNP from these
loci in our WHI-SHARe AA and HA populations. In AA
individuals, seven loci met the strict Bonferroni-correctedMinor/Major
Allele
Minor Allele
Frequency
Effect Size
(Standard Error) p Value
A/G 0.451 0.113 (0.025) 2.2 3 109
G/A 0.344 0.129 (0.026) 1.2 3 109
SL, T/G 0.379 0.141 (0.025) 3.0 3 1010
imputed SNPs is indicated. Effect size represents the effect of a minor allele on
ild 136.
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508 The American Journal of Human Genetics 91, 502–512, Septembsignificance threshold (p < 0.0028), whereas 12 of 16 loci
tested (75%) had p < 0.05 and the same direction of effect.
Notably, in several instances (HNF1A, IL6R, HNF4A, RORA,
SALL1 [MIM 602218], PSMG1 [MIM 605296], and BCL7B
[MIM 605846]), the allele associated with higher CRP is
more common among Africans than among Europeans.
In HA individuals, six loci met the Bonferroni significance
criteria for replication, whereas 9 of 13 (69%) were nomi-
nally associated with CRP at p < 0.05 and showed consis-
tent direction of effect. Eight (CRP, APOC1, LEPR, IL6R,
GCKR, NLRP3, IL1F10, and HNF4A) of 12 loci (67%)
showed consistency of CRP association across white, AA,
and HA individuals.Discussion
In the largest reported GWAS of CRP in United States
minority populations, we have identified and validated
in chromosomal region 6p21 an African TREM2 variant
associated with higher CRP in AA women. We also
demonstrate in AA individuals a strong admixture
association signal due to several polymorphisms (located
within the CRP region) that are independently associated
with CRP. As previously reported, the most significant of
these is specific to African ancestral populations and is
associated with higher CRP. Most loci (CRP, LEPR, IL1RN,
IL6R, GCKR, NLRP3, HNF1A, HNF4A, and APOC1) previ-
ously associated with CRP through GWASs of European
populations showed consistent patterns of association
with CRP in AA and HA individuals. Of the CRP loci
identified through GWASs of European, Japanese, or
AA individuals, the index SNPs at CRP, IL6R, HNF1A,
GCKR, TREM2, RORA, and HNF4A showed differences in
allele frequency between ancestral populations; the
African ancestral allele generally was associated with
higher CRP.TREM2 Is a Genetic Locus Associated with CRP in AA
Women
TREMs belong to a family of membrane-bound and soluble
receptors encoded by a gene cluster centromeric to the
HLA region on human chromosome 6.40,41 TREM-1 acti-
vates neutrophils and monocytes in response to bacterial
and fungal pathogens by signaling through the adaptor
protein DAP12, triggering secretion of proinflammatory
chemokines and cytokines, neutrophil degranulation,
and phagocytosis. TREM-2 is present on macrophages, mi-
croglia, and monocyte-derived dendritic cells and is
thought to negatively regulate macrophage cytokine
production and autoimmunity. TREM-2 deficiency in hu-
mans (Nasu-Hakola syndrome [MIM 221770]) is character-
ized by bone cysts and CNS demyelination, which leads to
dementia.42 TREM-1 and TREM-2 are also expressed consti-
tutively by hepatic macrophages and endothelial cells, and
they might have an important role in the inflammatory
response to bacterial infection.43 Given the influence ofer 7, 2012
Table 5. Association between TREM2 Haplotypes and CRP in WHI-SHARe AA Women
Haplotype rs7748513 rs2234253 Frequency Beta [95% CI] p Value
H1 A C 0.564 referent –
H2 G C 0.319 0.0642 [0.026, 0.102] 0.00098
H3 G A 0.116 0.1107 [0.056, 0.166] 7.86 3 105
The overall p value for TREM2 haplotype association with CRP ¼ 6.97 3 109. The following abbreviation is used: CI, confidence interval.gender and ethnicity on CRP, it is noteworthy that the
TREM2 variant associated with higher CRP is common
only among African ancestral populations and appears to
be confined to women only. Why this association would
be sex specific is unclear. All WHI-SHARe participants
were postmenopausal, and there was no evidence of inter-
action between exogenous sex-hormone use and the
TREM2 genotype on CRP (data not shown). Further evalu-
ation of the TREM2 genotype in larger samples of AA men
and women is needed for confirming the gender specificity
of the CRP effect.
Allelic Heterogeneity at the CRP Locus
Allelic heterogeneity at the CRP locus has been previously
demonstrated in single-cohort studies of EA and AA
adults.15 Of the common CRP SNPs identified by rese-
quencing, several in the CRP promoter region are strongly
associated with CRP levels and are correlated with the
independently associated CRP index SNPs observed in
WHI-SHARe. The CRP-increasing allele of rs16827466 is
in LD with a common African CRP promoter haplotype
tagged by rs3093058 (CRP-790 T allele), associated
with increased basal CRP transcriptional activity in
human hepatocytes.15 By contrast, rs7553007 is in LD
with a haplotype tagged by rs1205, located in the CRP 30
flanking region (CRP-3872). The same CRP-lowering
haplotype tagged by rs1205 has been associated with lower
CRP in AA and HA individuals44 and with lower promoter
activity.15 In Europeans, rs1205 is in perfect LD (r2 ¼ 1.0)
with the index SNP rs2794520 at the 1q23 CRP locus
previously reported in European GWASs.21 The CRP-
lowering allele of rs1205 (or rs287994520) is less common
in African populations than in Europeans and Hispanics
(see Table S1). A third CRP-lowering SNP rs1800947
(CRP-2667) is a synonymous coding variant15 that is
present in European, Asian, and Hispanic, but not African,
populations.15,44 Thus, interpopulation differences in CRP
might be attributable to allele-frequency differences at
several CRP SNPs, in which the allele associated with lower
CRP levels is more frequent in EA or HA individuals than in
AA individuals.
Population Genetic Analysis of the 1q23 Region
Containing CRP and DARC
The admixture mapping evidence in chromosomal region
1q23 suggests that this region harbors CRP-associated
alleles, which occur at disparate frequencies between theThe AmericanEuropean and African ancestral populations. Indeed, the
CRP-increasing variant rs16827466 occurs almost exclu-
sively in Africans, whereas alleles at rs16827466,
rs7553007, and rs2808634 also exhibit frequency differ-
ence between the HapMap CEU and YRI populations. It
is therefore reasonable to ask whether this pattern of diver-
gence is influenced by evolutionary forces other than
random drift.
CRP is located ~500 kb downstream of DARC, a locus
that represents a target of natural selection.45,46 In Africa,
homozygosity for a null allele (FY*O or rs2814778) is
known to confer resistance to vivax malaria; the null allele
is essentially fixed in sub-Saharan African populations but
is virtually absent in other parts of the world. Could some
of the CRP alleles have reached higher frequency in
Africans by hitchhiking on the FY*O haplotypes? Contra-
dicting this hypothesis, we found that LD between CRP
and DARC is low in both HapMap CEU and YRI popula-
tions (Figure S4). In contrast to FY*O, both rs7553007
and rs2808634 are polymorphic in HapMap CEU, YRI,
East Asian, and other populations, suggesting that these
variations predate the adaptive selection of the FY*O allele
~10,000 years ago.47 These observations suggest that
evolution at the CRP locus is most likely independent of
that at the DARC locus. Although methods based on
homozygosity or Fst do not present unambiguous signa-
ture of selection in CRP in any continental population,
the possibility of adaptive evolution cannot be excluded.
This is because most existing methods for detecting signa-
ture of selection focus on classic sweeps, in which a benefi-
cial mutation is rapidly driven toward fixation.48 Variation
in CRP shows a more complex pattern: multiple variants
influence the phenotype. Additionally, the complex popu-
lation genetic structure within Africa and the admixing
history of AA individuals require selection studies for care-
fully modeling the demographic history.
Although the strong correlation between CRP and
obesity accounts for some of the differences in CRP across
populations,12,15 genetic factors also appear to contribute
to the interethnic phenotypic differences. Intriguingly,
almost all CRP-increasing variants occur at a higher
frequency in African populations than they do in Euro-
pean populations (see Table S1).This is consistent with
a model in which standing variation is subjected to popu-
lation-specific directional selection: CRP-increasing vari-
ants become adaptive in Africans while CRP-decreasing
variants spread in Europeans.Journal of Human Genetics 91, 502–512, September 7, 2012 509
CRP Genetic Loci and the Role of Inflammation in
Cardiovascular and Metabolic Disease
Of the approximately 20 loci associated with CRP, many of
these genes involve pathways related to either innate
immunity (e.g., CRP, IL6R, IL6, NLRP3, IL1RN, IRF1, and
TREM2) or lipid and glucose metabolism (e.g., APOC1,
HNF1A, LEPR, GCKR, HNF4A, RORA, and PTPN2), high-
lighting the connection between inflammation and meta-
bolic dysregulation. Interethnic differences in CRP and the
underlying genetic architecture of CRP have potential
implications for cardiovascular-risk stratification, predic-
tion, and treatment, such as statin eligibility. AA individ-
uals have higher CVD risk than do non-Hispanic whites
despite higher high-density lipoprotein (HDL) cholesterol
and lower triglyceride levels.49–51 Chronic low-grade
inflammation might contribute to increased cardiovas-
cular-disease risk and other health disparities among these
minority United States populations.11 The metabolic
syndrome paradoxically has a lower prevalence in AA indi-
viduals than in EA individuals, but there is a greater differ-
ence in CRP among AA individuals with and without the
metabolic syndrome than there is among EA individuals
with and without metabolic syndrome.52
CRP biosynthesis is largely under the control of
IL-6, which together with IL-1b activates transcription
factors that induce CRP transcription. The IL-6-receptor
p.Asp358Ala polymorphism encoded by IL6R rs8192284
is known to dampen the inflammatory effect of IL-6
and lower CRP and has been associated with a lower risk
of coronary heart disease (CHD).53 These results suggest
not only a causal role of IL-6-receptor signaling in CHD
pathogenesis but also that IL-6-receptor blockade with
agents such as tocilizumab might provide a novel
therapeutic approach to CHD prevention. Notably, the
cardioprotective IL-6-receptor p.Asp358Ala variant is
considerably less common among AA individuals than it
is among whites and HA individuals (Table S1). Therefore,
IL-6-receptor blockade might represent a particularly
important therapeutic target for CHD prevention in AA
individuals.Supplemental Data
Supplemental Data include four figures and one table and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
The Women’s Health Initiative (WHI) program is funded by the
National Heart, Lung, and Blood Institute, National Institutes of
Health, and the United States Department of Health and Human
Services through contracts HHSN268201100046C, HHSN2682011
00001C, HHSN268201100002C, HHSN268201100003C, HHSN2
68201100004C, and HHSN271201100004C. The authors thank
the WHI investigators and staff for their dedication and the study
participants for making the program possible. A listing of
WHI investigators can be found at http://www.whiscience.org/
publications/WHI_investigators_shortlist_2010-2015.pdf.510 The American Journal of Human Genetics 91, 502–512, SeptembReceived: June 10, 2012
Revised: July 8, 2012
Accepted: July 26, 2012
Published online: August 30, 2012Web Resources
The URLs for data presented herein are as follows:
Frappe, http://med.stanford.edu/tanglab/software/frappe.html
International HapMap Project, http://hapmap.ncbi.nlm.nih.gov/
MaCH, http://www.sph.umich.edu/csg/yli/mach/
Monocyte eQTL database, http://genecanvas.ecgene.net/uploads/
ForReview/
NHLBI CARe Consortium, http://www.broadinstitute.org/gen_
analysis/care/index.php/
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org
PLINK, http://pngu.mgh.harvard.edu/~purcell/plink/
USCS Genome Browser, http://genome.ucsc.edu/References
1. Pearson, T.A., Mensah, G.A., Alexander, R.W., Anderson, J.L.,
Cannon, R.O., 3rd, Criqui, M., Fadl, Y.Y., Fortmann, S.P.,
Hong, Y., Myers, G.L., et al; Centers for Disease Control and
Prevention; American Heart Association. (2003). Markers of
inflammation and cardiovascular disease: Application to clin-
ical and public health practice: A statement for healthcare
professionals from the Centers for Disease Control and
Prevention and the American Heart Association. Circulation
107, 499–511.
2. Ridker, P.M., Buring, J.E., Rifai, N., and Cook, N.R. (2007).
Development and validation of improved algorithms for the
assessment of global cardiovascular risk in women: the Rey-
nolds Risk Score. JAMA 297, 611–619.
3. Ridker, P.M., Paynter, N.P., Rifai, N., Gaziano, J.M., and Cook,
N.R. (2008). C-reactive protein and parental history improve
global cardiovascular risk prediction: The Reynolds Risk Score
for men. Circulation 118, 2243–2251, 4p, 2251.
4. Ford, E.S., Giles, W.H., Myers, G.L., Rifai, N., Ridker, P.M., and
Mannino, D.M. (2003). C-reactive protein concentration
distribution among US children and young adults: Findings
from the National Health and Nutrition Examination Survey,
1999-2000. Clin. Chem. 49, 1353–1357.
5. Albert, M.A., and Ridker, P.M. (2006). C-reactive protein as
a risk predictor: do race/ethnicity and gender make a differ-
ence? Circulation 114, e67–e74.
6. Lakoski, S.G., Cushman, M., Criqui, M., Rundek, T., Blumen-
thal, R.S., D’Agostino, R.B., Jr., and Herrington, D.M. (2006).
Gender and C-reactive protein: Data from the Multiethnic
Study of Atherosclerosis (MESA) cohort. Am. Heart J. 152,
593–598.
7. Khera, A., McGuire, D.K., Murphy, S.A., Stanek, H.G., Das,
S.R., Vongpatanasin, W., Wians, F.H., Jr., Grundy, S.M., and
de Lemos, J.A. (2005). Race and gender differences in C-reac-
tive protein levels. J. Am. Coll. Cardiol. 46, 464–469.
8. Cushman, M., McClure, L.A., Howard, V.J., Jenny, N.S.,
Lakoski, S.G., and Howard, G. (2009). Implications of
increased C-reactive protein for cardiovascular risk stratifica-
tion in black and white men and women in the US. Clin.
Chem. 55, 1627–1636.er 7, 2012
9. Albert, M.A., Glynn, R.J., Buring, J., and Ridker, P.M. (2004).
C-reactive protein levels among women of various ethnic
groups living in the United States (from the Women’s Health
Study). Am. J. Cardiol. 93, 1238–1242.
10. Mensah, G.A., Mokdad, A.H., Ford, E.S., Greenlund, K.J., and
Croft, J.B. (2005). State of disparities in cardiovascular health
in the United States. Circulation 111, 1233–1241.
11. Miller, M., Zhan, M., and Havas, S. (2005). High attributable
risk of elevated C-reactive protein level to conventional
coronary heart disease risk factors: The Third National Health
and Nutrition Examination Survey. Arch. Intern. Med. 165,
2063–2068.
12. Wee, C.C., Mukamal, K.J., Huang, A., Davis, R.B., McCarthy,
E.P., and Mittleman, M.A. (2008). Obesity and C-reactive
protein levels among white, black, and hispanic US adults.
Obesity (Silver Spring) 16, 875–880.
13. Shah, T., Newcombe, P., Smeeth, L., Addo, J., Casas, J.P.,
Whittaker, J., Miller, M.A., Tinworth, L., Jeffery, S., Strazzullo,
P., et al. (2010). Ancestry as a determinant of mean population
C-reactive protein values: Implications for cardiovascular risk
prediction. Circ Cardiovasc Genet 3, 436–444.
14. Rodriguez, F., Peralta, C.A., Green, A.R., and Lo´pez, L. (2012).
Comparison of C-reactive protein levels in less versus more
acculturated Hispanic adults in the United States (from the
National Health and Nutrition Examination Survey 1999-
2008). Am. J. Cardiol. 109, 665–669.
15. Carlson, C.S., Aldred, S.F., Lee, P.K., Tracy, R.P., Schwartz, S.M.,
Rieder, M., Liu, K., Williams, O.D., Iribarren, C., Lewis, E.C.,
et al. (2005). Polymorphisms within the C-reactive protein
(CRP) promoter region are associated with plasma CRP levels.
Am. J. Hum. Genet. 77, 64–77.
16. Retterstol, L., Eikvar, L., and Berg, K. (2003). A twin study of
C-Reactive Protein compared to other risk factors for coronary
heart disease. Atherosclerosis 169, 279–282.
17. Pankow, J.S., Folsom, A.R., Cushman, M., Borecki, I.B., Hop-
kins, P.N., Eckfeldt, J.H., and Tracy, R.P. (2001). Familial and
genetic determinants of systemic markers of inflammation:
The NHLBI family heart study. Atherosclerosis 154, 681–689.
18. Dupuis, J., Larson, M.G., Vasan, R.S., Massaro, J.M., Wilson,
P.W., Lipinska, I., Corey, D., Vita, J.A., Keaney, J.F., Jr., and
Benjamin, E.J. (2005). Genome scan of systemic biomarkers
of vascular inflammation in the Framingham Heart Study:
evidence for susceptibility loci on 1q. Atherosclerosis 182,
307–314.
19. Fox, E.R., Benjamin, E.J., Sarpong, D.F., Rotimi, C.N., Wilson,
J.G., Steffes, M.W., Chen, G., Adeyemo, A., Taylor, J.K.,
Samdarshi, T.E., and Taylor, H.A., Jr. (2008). Epidemiology,
heritability, and genetic linkage of C-reactive protein in
African Americans (from the Jackson Heart Study). Am. J.
Cardiol. 102, 835–841.
20. Naitza, S., Porcu, E., Steri, M., Taub, D.D., Mulas, A., Xiao, X.,
Strait, J., Dei, M., Lai, S., Busonero, F., et al. (2012). A genome-
wide association scan on the levels of markers of inflamma-
tion in Sardinians reveals associations that underpin its
complex regulation. PLoS Genet. 8, e1002480.
21. Dehghan, A., Dupuis, J., Barbalic, M., Bis, J.C., Eiriksdottir, G.,
Lu, C., Pellikka, N., Wallaschofski, H., Kettunen, J., Henne-
man, P., et al. (2011). Meta-analysis of genome-wide associa-
tion studies in >80 000 subjects identifies multiple loci for
C-reactive protein levels. Circulation 123, 731–738.
22. Okada, Y., Takahashi, A., Ohmiya, H., Kumasaka, N., Kama-
tani, Y., Hosono, N., Tsunoda, T., Matsuda, K., Tanaka, T.,The AmericanKubo, M., et al. (2011). Genome-wide association study for
C-reactive protein levels identified pleiotropic associations
in the IL6 locus. Hum. Mol. Genet. 20, 1224–1231.
23. Ridker, P.M., Pare, G., Parker, A., Zee, R.Y., Danik, J.S., Buring,
J.E., Kwiatkowski, D., Cook, N.R., Miletich, J.P., and Chasman,
D.I. (2008). Loci related to metabolic-syndrome pathways
including LEPR,HNF1A, IL6R, and GCKR associate with
plasma C-reactive protein: The Women’s Genome Health
Study. Am. J. Hum. Genet. 82, 1185–1192.
24. Doumatey, A.P., Chen, G., Tekola Ayele, F., Zhou, J., Erdos, M.,
Shriner, D., Huang, H., Adeleye, J., Balogun, W., Fasanmade,
O., et al. (2012). C-reactive protein (CRP) promoter polymor-
phisms influence circulating CRP levels in a genome-wide
association study of African Americans. Hum. Mol. Genet.
21, 3063–3072.
25. Johnson, N.A., Coram, M.A., Shriver, M.D., Romieu, I., Barsh,
G.S., London, S.J., and Tang, H. (2011). Ancestral components
of admixed genomes in a Mexican cohort. PLoS Genet. 7,
e1002410.
26. Hays, J., Hunt, J.R., Hubbell, F.A., Anderson, G.L., Limacher,
M., Allen, C., and Rossouw, J.E. (2003). The Women’s Health
Initiative recruitment methods and results. Ann. Epidemiol.
13 (9, Suppl), S18–S77.
27. Li, Y., Willer, C.J., Ding, J., Scheet, P., and Abecasis, G.R.
(2010). MaCH: Using sequence and genotype data to estimate
haplotypes and unobserved genotypes. Genet. Epidemiol. 34,
816–834.
28. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira,
M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly,
M.J., and Sham, P.C. (2007). PLINK: A tool set for whole-
genome association and population-based linkage analyses.
Am. J. Hum. Genet. 81, 559–575.
29. Thornton, T., and McPeek, M.S. (2010). ROADTRIPS: Case-
control association testing with partially or completely
unknown population and pedigree structure. Am. J. Hum.
Genet. 86, 172–184.
30. Price, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E.,
Shadick, N.A., and Reich, D. (2006). Principal components
analysis corrects for stratification in genome-wide association
studies. Nat. Genet. 38, 904–909.
31. Tang, H., Peng, J., Wang, P., and Risch, N.J. (2005). Estimation
of individual admixture: Analytical and study design consider-
ations. Genet. Epidemiol. 28, 289–301.
32. Cann, H.M., de Toma, C., Cazes, L., Legrand, M.F., Morel, V.,
Piouffre, L., Bodmer, J., Bodmer, W.F., Bonne-Tamir, B., Cam-
bon-Thomsen, A., et al. (2002). A human genome diversity
cell line panel. Science 296, 261–262.
33. International HapMap Consortium. (2003). The International
HapMap Project. Nature 426, 789–796.
34. Tang, H., Coram, M., Wang, P., Zhu, X., and Risch, N. (2006).
Reconstructing genetic ancestry blocks in admixed individ-
uals. Am. J. Hum. Genet. 79, 1–12.
35. Johnson, N.A. (2011). Efficient models and algorithms for
problems in genomics. PhD thesis, Stanford University,
Stanford, CA.
36. Pe’er, I., Yelensky, R., Altshuler, D., and Daly, M.J. (2008).
Estimation of the multiple testing burden for genomewide
association studies of nearly all common variants. Genet.
Epidemiol. 32, 381–385.
37. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: Fast and
efficient meta-analysis of genomewide association scans.
Bioinformatics 26, 2190–2191.Journal of Human Genetics 91, 502–512, September 7, 2012 511
38. Zeller, T., Wild, P., Szymczak, S., Rotival, M., Schillert, A., Cas-
tagne, R., Maouche, S., Germain, M., Lackner, K., Rossmann,
H., et al. (2010). Genetics and beyond—the transcriptome of
human monocytes and disease susceptibility. PLoS ONE 5,
e10693.
39. Gonza´lez-Pe´rez, A., and Lo´pez-Bigas, N. (2011). Improving the
assessment of the outcome of nonsynonymous SNVs with
a consensus deleteriousness score, Condel. Am. J. Hum.
Genet. 88, 440–449.
40. Ford, J.W., and McVicar, D.W. (2009). TREM and TREM-like
receptors in inflammation and disease. Curr. Opin. Immunol.
21, 38–46.
41. Allcock, R.J., Barrow, A.D., Forbes, S., Beck, S., and Trowsdale,
J. (2003). The human TREM gene cluster at 6p21.1 encodes
both activating and inhibitory single IgV domain receptors
and includes NKp44. Eur. J. Immunol. 33, 567–577.
42. Paloneva, J., Manninen, T., Christman, G., Hovanes, K.,
Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda,
R., Salmaggi, A., et al. (2002). Mutations in two genes encod-
ing different subunits of a receptor signaling complex result
in an identical disease phenotype. Am. J. Hum. Genet. 71,
656–662.
43. Sharif, O., and Knapp, S. (2008). From expression to signaling:
Roles of TREM-1 and TREM-2 in innate immunity and bacte-
rial infection. Immunobiology 213, 701–713.
44. Crawford, D.C., Sanders, C.L., Qin, X., Smith, J.D., Shephard,
C., Wong, M., Witrak, L., Rieder, M.J., and Nickerson, D.A.
(2006). Genetic variation is associated with C-reactive protein
levels in the Third National Health and Nutrition Examina-
tion Survey. Circulation 114, 2458–2465.
45. Livingstone, F.B. (1984). The Duffy blood groups, vivax ma-
laria, and malaria selection in human populations: A review.
Hum. Biol. 56, 413–425.512 The American Journal of Human Genetics 91, 502–512, Septemb46. Hamblin, M.T., Thompson, E.E., and Di Rienzo, A. (2002).
Complex signatures of natural selection at the Duffy blood
group locus. Am. J. Hum. Genet. 70, 369–383.
47. Hamblin, M.T., and Di Rienzo, A. (2000). Detection of the
signature of natural selection in humans: evidence from the
Duffy blood group locus. Am. J. Hum. Genet. 66, 1669–1679.
48. Hernandez, R.D., Kelley, J.L., Elyashiv, E., Melton, S.C., Auton,
A., McVean, G., Sella, G., and Przeworski, M.; 1000 Genomes
Project. (2011). Classic selective sweeps were rare in recent
human evolution. Science 331, 920–924.
49. Roger, V.L., Go, A.S., Lloyd-Jones, D.M., Benjamin, E.J., Berry,
J.D., Borden, W.B., Bravata, D.M., Dai, S., Ford, E.S., Fox, C.S.,
et al; American Heart Association Statistics Committee and
Stroke Statistics Subcommittee. (2012). Heart disease and
stroke statistics—2012 update: A report from the American
Heart Association. Circulation 125, e2–e220.
50. Chambless, L.E., Folsom, A.R., Sharrett, A.R., Sorlie, P.,
Couper, D., Szklo, M., and Nieto, F.J. (2003). Coronary heart
disease risk prediction in the Atherosclerosis Risk in Commu-
nities (ARIC) study. J. Clin. Epidemiol. 56, 880–890.
51. Chambless, L.E., Heiss, G., Shahar, E., Earp, M.J., and Toole, J.
(2004). Predictionof ischemic stroke risk in theAtherosclerosis
Risk in Communities Study. Am. J. Epidemiol. 160, 259–269.
52. DeBoer, M.D., Gurka,M.J., and Sumner, A.E. (2011). Diagnosis
of the metabolic syndrome is associated with disproportion-
ately high levels of high-sensitivity C-reactive protein in
non-Hispanic black adolescents: An analysis of NHANES
1999-2008. Diabetes Care 34, 734–740.
53. Hingorani, A.D., and Casas, J.P.; Interleukin-6 Receptor
Mendelian Randomisation Analysis (IL6R MR) Consortium.
(2012). The interleukin-6 receptor as a target for prevention
of coronary heart disease: A mendelian randomisation anal-
ysis. Lancet 379, 1214–1224.er 7, 2012
